The global Transfection Reagent & Equipment Market size is estimated to reach USD 1.08 billion by 2022, exhibiting a 7.4% CAGR during the forecast period. The primary factor for the growth of this segment is the rising demand for the production of the recombinant protein.
Advancements in the clinical development of biopharmaceuticals, is anticipated to boost the demand for gene analysis and gene expression studies for the purpose of bio-authenticity and investigative analysis. The aforementioned factor is attributive to drive the segment revenue potentially in the coming years.
Patent cliff generated in recent years is pronouncing the need for production of several moieties which depends on the laboratory analysis thus inducing industrial growth in this market. Anticipated rise in the analytical methods is expected to increase the adoption of such technologies in the coming years.
Additionally, with established healthcare infrastructure and reimbursement policy, many pharma companies are expanding their business in western geographic segments which would induce innovation and growth in the biotechnology industry over the forecasted period.
Electroporation method for conducting transfection process holds the largest share of the revenue. The larger share is attributive to its diverse versatility in application, user-friendliness, and consequent higher implementation of this technique. However, the misuse of this method has caused cell damage which is expected to slow down its adoption.
Liposomal method is second only to the electroporation method of transfection. The other segments for the implementation of method includes adenoviral vectors and particle bombardment which are expected to provide positive growth in the forecasted period.
Bombardment equipment and particle acceleration have witnessed a reduction in the cost over the past years which will boost its market penetration. This method is expected to grow at the fastest rate owing to increasing investment in order to bring about technological innovations in this market.
Gene expression accounted for the largest share of revenue in 2016 as a result of larger use of the technology in this segment. Vaccine biopharmaceuticals production requires substantial usage of gene expression methods based on the principles of transfection.
Proteomic analyzers and cytology-based programs (for research purpose) are expected to witness demand in biomedical and oncology studies. This factor is expected to fuel progress in the coming years.
North American region witnessed highest penetration in 2016 owing to the presence of large number of research and biopharmaceutical production institutes, biosimilar drugs, vaccines, and clinical organizations for R&D.
With the rise in number of academic institutes engaged in basic research for protein and genetic research which are highly supported by the government, the market revenue for transfection is anticipated to witness potential increment. Also, a large number of cancer research and specialized biomedical institute provides a platform for the development of this technology.
Europe with respect to market share is close to North America and has gained significantly high revenue as per the estimation. With favorable government policy, large-scale gene expression analysis is widely implemented in this region. Also, large-scale development in reverse transfection has provided a strong base for penetration of the products in this region.
Asia-Pacific region is expected to witness fastest growth over the forecast period owing to progress in healthcare infrastructure, for example, setting up of bio-incubators for research purpose, rise in government funding for basic research held in academic institutions, increasing adoption of proteomics and cytological expression.
Roche, Promega and Life Technologies (a subsidiary of Thermo Fisher) are renowned players operating in this market. These players are engaged in implementing strategic initiatives such as product development, diversification, vertical and horizontal integration, and in some cases divestiture.
Other companies that are operating in this market are Lonza, Qiagen, Mirus Bio LLC, OriGene Technologies, EMD Millipore, VWR International, BTX and SignaGen Laboratory.
Transfection Reagent & Equipment Product Outlook (Revenue, USD Million, 2014 - 2022)
Transfection Reagent & Equipment Method Outlook (Revenue, USD Million, 2014 - 2022)
• Particle Bombardment
• Adenoviral Vectors
• Direct Microinjection
• Calcium phosphate
• DEAE - dextran
• Magnetic Beads
• Activated Dendrimers
Transfection Reagent & Equipment Application Outlook (Revenue, USD Million, 2014 - 2022)
• Gene Expression Studies
• Protein Production
• Transgenic Models
• Therapeutic Delivery
• Cancer Research
• Biomedical Research
Transfection Reagent & Equipment Regional Outlook (Revenue, USD Million, 2014 - 2022)
• North America
• Asia Pacific
• Latin America
• Middle East & Africa
• South Africa
Research Support Specialist, USA